Geoffrey R. Oxnard, MD | Authors

Lincoln Community Health Center Pharmacy

PO BOX 51998

Articles

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

April 30, 2010

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).